Profile data is unavailable for this security.
About the company
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company’s lead product candidate, XDEMVY is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The Company investigating the development of its product candidates to address targeted diseases with high unmet medical needs, which include TP-03 for the potential treatment of Meibomian Gland Disease (MGD), TP-04, a novel gel formulation of lotilaner for the potential treatment of rosacea, and TP-05, a novel investigative oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction.
- Revenue in USD (TTM)17.45m
- Net income in USD-135.89m
- Incorporated2016
- Employees244.00
- LocationTarsus Pharmaceuticals Inc15440 Laguna Canyon RoadIRVINE 92618United StatesUSA
- Phone+1 (949) 409-9820
- Fax+1 (302) 531-3150
- Websitehttps://www.tarsusrx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vir Biotechnology Inc | 79.60m | -539.44m | 1.30bn | 587.00 | -- | 0.8375 | -- | 16.31 | -4.01 | -4.01 | 0.5916 | 11.39 | 0.0357 | -- | -- | 135,603.10 | -24.19 | -0.6081 | -27.80 | -0.7192 | 98.85 | -- | -677.69 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
| Belite Bio Inc (ADR) | 0.00 | -31.63m | 1.30bn | 20.00 | -- | 13.80 | -- | -- | -1.24 | -1.24 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -45.54 | -- | -47.50 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
| Gyre Therapeutics Inc | 0.00 | -44.24m | 1.34bn | 7.00 | -- | -- | -- | -- | -20.60 | -20.60 | 0.00 | 1.39 | 0.00 | -- | -- | 0.00 | -215.90 | -58.25 | -235.61 | -72.12 | -- | -- | -- | -817.06 | -- | -- | 0.00 | -- | -89.18 | -4.85 | 90.63 | -- | -- | -- |
| 4D Molecular Therapeutics Inc | 20.72m | -100.84m | 1.35bn | 147.00 | -- | 3.68 | -- | 65.00 | -2.58 | -2.58 | 0.5438 | 7.15 | 0.0689 | -- | -- | 140,972.80 | -33.52 | -32.67 | -35.57 | -34.90 | -- | -- | -486.59 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| ANI Pharmaceuticals Inc | 486.82m | 15.48m | 1.38bn | 642.00 | 79.93 | 3.11 | 17.89 | 2.83 | 0.821 | 0.821 | 26.17 | 22.35 | 0.5849 | 1.68 | 2.97 | 758,280.40 | 2.26 | -2.83 | 2.65 | -3.35 | 62.71 | 60.18 | 3.86 | -6.15 | 2.81 | 1.79 | 0.3843 | -- | 53.87 | 19.28 | 131.25 | 0.1754 | 9.08 | -- |
| Pacira Biosciences Inc | 681.75m | 70.47m | 1.38bn | 711.00 | 22.88 | 1.55 | 9.52 | 2.02 | 1.30 | 1.30 | 12.11 | 19.18 | 0.4389 | 1.93 | 7.00 | 958,866.40 | 4.54 | 3.35 | 4.84 | 3.98 | 73.15 | 72.63 | 10.34 | 8.57 | 4.78 | 51.11 | 0.3684 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
| Arcus Biosciences Inc | 117.00m | -307.00m | 1.39bn | 577.00 | -- | 2.49 | -- | 11.86 | -4.15 | -4.15 | 1.58 | 6.12 | 0.0959 | -- | 2.89 | 202,773.00 | -25.16 | -15.85 | -29.76 | -18.25 | -- | -- | -262.39 | -103.46 | -- | -- | 0.00 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
| Tarsus Pharmaceuticals Inc | 17.45m | -135.89m | 1.41bn | 244.00 | -- | 6.49 | -- | 80.87 | -4.58 | -4.58 | 0.5939 | 5.76 | 0.0707 | -- | 1.64 | 71,504.10 | -55.09 | -31.56 | -61.63 | -33.82 | 90.87 | -- | -778.89 | -242.59 | 6.85 | -- | 0.1315 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
| Day One Biopharmaceuticals Inc | 0.00 | -208.94m | 1.43bn | 174.00 | -- | 4.83 | -- | -- | -2.50 | -2.50 | 0.00 | 3.40 | 0.00 | -- | -- | 0.00 | -64.27 | -- | -69.93 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
| Kiniksa Pharmaceuticals Ltd | 301.77m | 8.65m | 1.44bn | 297.00 | 237.79 | 3.32 | 132.33 | 4.76 | 0.0852 | 0.0852 | 4.16 | 6.10 | 0.627 | 1.46 | 25.77 | 1,016,067.00 | 1.80 | -16.49 | 2.01 | -18.72 | 87.75 | -- | 2.87 | -53.64 | 3.79 | -- | 0.00 | -- | 22.74 | -- | -92.32 | -- | -52.35 | -- |
| Ligand Pharmaceuticals Inc | 118.31m | 96.34m | 1.44bn | 58.00 | 15.35 | 1.76 | 10.97 | 12.20 | 5.23 | 5.23 | 6.52 | 45.55 | 0.1372 | 0.5475 | 4.11 | 2,039,879.00 | 11.17 | 12.32 | 11.98 | 12.99 | 91.82 | 81.65 | 81.43 | 80.32 | 19.51 | -- | 0.00 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
| Akero Therapeutics Inc | 0.00 | -151.76m | 1.45bn | 55.00 | -- | 2.19 | -- | -- | -2.85 | -2.85 | 0.00 | 9.60 | 0.00 | -- | -- | 0.00 | -32.40 | -37.73 | -33.78 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0446 | -- | -- | -- | -35.46 | -- | -- | -- |
| Xencor Inc | 168.34m | -126.09m | 1.46bn | 280.00 | -- | 2.16 | -- | 8.66 | -2.10 | -2.10 | 2.79 | 10.96 | 0.1872 | -- | 8.36 | 601,207.10 | -14.04 | -3.70 | -15.30 | -4.12 | -- | -- | -75.00 | -15.92 | -- | -- | 0.0304 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
| Morphic Holding Inc | 0.00 | -161.25m | 1.47bn | 124.00 | -- | 2.21 | -- | -- | -3.49 | -3.49 | 0.00 | 13.25 | 0.00 | -- | -- | 0.00 | -28.67 | -22.69 | -29.49 | -24.99 | -- | -- | -- | -258.10 | -- | -- | 0.00 | -- | -99.26 | -31.11 | -157.61 | -- | 13.50 | -- |
| Neumora Therapeutics Inc | 0.00 | -254.02m | 1.50bn | 120.00 | -- | 3.54 | -- | -- | -2.44 | -2.44 | 0.00 | 2.66 | 0.00 | -- | -- | 0.00 | -60.32 | -- | -63.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
| Dynavax Technologies Corp | 232.28m | -6.39m | 1.52bn | 408.00 | -- | 2.43 | -- | 6.56 | -0.0733 | -0.0733 | 1.65 | 4.80 | 0.2343 | 0.89 | 2.50 | 569,323.50 | -0.6444 | 4.16 | -0.7216 | 5.71 | 78.40 | 64.83 | -2.75 | 9.19 | 12.96 | -- | 0.2636 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
Data as of May 09 2024. Currency figures normalised to Tarsus Pharmaceuticals Inc's reporting currency: US Dollar USD
53.30%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RTW Investments LPas of 31 Dec 2023 | 3.15m | 8.41% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 2.24m | 5.96% |
| Cormorant Asset Management LPas of 31 Dec 2023 | 2.22m | 5.92% |
| Tang Capital Management LLCas of 31 Dec 2023 | 2.20m | 5.88% |
| Cowen & Co. LLCas of 31 Mar 2024 | 2.12m | 5.66% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 1.94m | 5.17% |
| Paradigm BioCapital Advisors LPas of 12 Jan 2024 | 1.93m | 5.14% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.56m | 4.15% |
| Jennison Associates LLCas of 31 Mar 2024 | 1.33m | 3.55% |
| Perceptive Advisors LLCas of 31 Dec 2023 | 1.30m | 3.46% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
